TXMD News and Press, TherapeuticsMD Inc. From 11/13/23

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

TherapeuticsMD Inc. (TXMD) is expected to report for Q3 2023

2023-08-14 06:52:04 ET Therapeutics MD press release ( NASDAQ: TXMD ): Q2 GAAP EPS of -$0.24. License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended June 30, 2023, compared to $0.3 ...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. “The Company’s transformation into a royalty-...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-23 09:00:35 ET Summary TXMD is a pharmaceutical company that experienced a tremendous transformation in the last year, fully transforming into a royalty-only company. The company sold all its assets and paid down all its debt and is now expecting 8% of royalties plus $30 m...

2023-05-15 16:54:32 ET Therapeutics MD press release ( NASDAQ: TXMD ): Q1 GAAP EPS of -$0.24 beats by $0.87 . License and service revenues from continuing operations, which are revenues related to license agreements, were $0.4 million for the quarter ended March 31, 20...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Net Loss fro...

2023-04-10 09:47:38 ET Therapeutics MD press release ( NASDAQ: TXMD ): FY GAAP EPS of -$0.12. As of December 31, 2022, the Company’s cash on hand totaled $38.1 million compared with $64.9 million as of December 31, 2021. For further details see: Therapeuti...

TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. “As a result of the transaction with Mayne Pharma Gro...